MODAFINIL

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H15NO2S
Molecular Weight	273.35
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=YFGHCGITMMYXAQ-UHFFFAOYSA-N

InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H15NO2S
Molecular Weight	273.35
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19689169http://www.drugbank.ca/drugs/DB00745
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf

Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. Modafinil is not indicated for complaints of lack of energy or fatigue; but it appears to be very helpful for some patients. Also, it has been used in the treatment of hypersomnia, a disorder in which patients lack the capacity for meaningful sleep and may require ten or more hours per day. Recent studies have have found that modafinil may help recovering cocaine addicts fight their addiction. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors. Modafinil is indicated for the improvement of wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061	Inhibitor 8228	51.79 µM [IC50]
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061	Inhibitor 8228	51.79 µM [IC50]
Dopamine transporter 179 Target ID: CHEMBL238 Sources: http://www.drugbank.ca/drugs/DB00745	Inhibitor 8228	13.0 µM [Ki]
Dopamine transporter 179 Target ID: CHEMBL238 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021875s023lbl.pdf	Inhibitor 8228	4.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Narcolepsy 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf	Primary	Approved 8360	PROVIGIL Approved Use Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Launch Date 9.1437118E11
Obstructive sleep apnea 6 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf	Primary	Approved 8360	PROVIGIL Approved Use Provigil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Launch Date 9.1437118E11
Sleep disorder 20 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19689169	Primary	Approved 8360	NUVIGIL Approved Use NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. Launch Date 1.18186561E12

C_max

Value	Dose	Analyte	Population
7.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
10 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
4.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
105.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
136.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	250 mg 1 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
150.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
189.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
23.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
56.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
142.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
146 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
15.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
40.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
43.8 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT
75.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19133704	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		ARMODAFINIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: idiopathic hypersomnia Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	Disc. AE: Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Stevens-Johnson syndrome (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29734973
400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 6 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 4 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	Disc. AE: Adverse event... AEs leading to discontinuation/dose reduction: Adverse event Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	Disc. AE: Rash, Angioneurotic edema... AEs leading to discontinuation/dose reduction: Rash (2%) Angioneurotic edema (1%) Hyperhidrosis (1%) Rash papular (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6

AEs

AE	Significance	Dose	Population
Stevens-Johnson syndrome	1 patient Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29734973	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: idiopathic hypersomnia Age Group: 21 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/29734973
Adverse event	Disc. AE	400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19133704	healthy, 21–40 years n = 4 Health Status: healthy Age Group: 21–40 years Sex: M Population Size: 4 Sources: https://pubmed.ncbi.nlm.nih.gov/19133704
Headache	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf
Angioneurotic edema	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Hyperhidrosis	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Rash papular	1% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6
Rash	2% Disc. AE	150 mg 1 times / day steady, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: steady Dose: 150 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6	unhealthy n = 645 Health Status: unhealthy Population Size: 645 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf Page: p.6

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:77590	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:77590
ZINC	ZINC000003831139	http://zinc15.docking.org/substances/ZINC000003831139

PubMed

Title	Date	PubMed
Off-label uses of modafinil.	2001 Aug	11481196
An enantioselective assay for (+/-)-modafinil.	2001 Aug	11451649
Methylphenidate and narcolepsy: new indication. When modafinil fails.	2001 Feb	11503860
Sleep disorders.	2001 Feb	11471763
Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.	2001 Feb	11211372
Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil.	2001 Jul	11518012
Modafinil and pramipexole-associated somnolence.	2001 Jul	11481716
Comparison in symptoms between aged and younger patients with narcolepsy.	2001 Jun	11422857
Practice parameters for the treatment of narcolepsy: an update for 2000.	2001 Jun 15	11403530
Dopaminergic role in stimulant-induced wakefulness.	2001 Mar 1	11222668
Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.	2002	12779190
Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.	2002 Apr	11936571
Discriminative-stimulus effects of modafinil in cocaine-trained humans.	2002 Aug 1	12127202
The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor.	2002 Feb	11856342
Narcolepsy and psychopathology: is there an association?	2002 Jul	14592199
Attention deficit disorder in adults.	2002 Jun	12238735
Gateways to Clinical Trials. June 2002.	2002 Jun	12168506
Secondary narcolepsy in children with brain tumors.	2002 Jun 15	12071545
Modafinil affects mood, but not cognitive function, in healthy young volunteers.	2003 Apr	12672167
Modafinil in children with attention-deficit hyperactivity disorder.	2003 Aug	14580657
By the way, doctor. What can you tell me about the new drug Provigil? I've read that it helps people stay awake without feeling jittery. For those of us who work a lot of overtime, it sounds like a dream come true.	2003 Jan	12543593
Modafinil maintains waking in the fruit fly drosophila melanogaster.	2003 Mar 15	12683471
Modafinil increases histamine release in the anterior hypothalamus of rats.	2003 Mar 20	12614915
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.	2003 May 1	12681523
Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.	2003 Sep-Oct	14520165
Anti-narcoleptic agent modafinil and its sulfone: a novel facile synthesis and potential anti-epileptic activity.	2004 Aug	15260124
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life.	2007	17632651
Chest tightness and palpitations associated with modafinil and consumption of free glutamate.	2008 Apr	18381922
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.	2009 Feb	19149817
Open-label pilot study of modafinil for methamphetamine dependence.	2009 Oct	19745650
Effects of modafinil on the sleep EEG depend on Val158Met genotype of COMT.	2010 Aug	20815183
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage of NUVIGIL (armodafinil) for each indication is as follows: obstructive sleep apnea or Narcolepsy: 150 mg to 250 mg once a day in the morning. Shift work disorder: 150 mg once a day, taken approximately one hour prior to start of the work shift.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:03:11 UTC 2023` Edited by `admin` on `Wed Jul 05 23:03:11 UTC 2023`
Record UNII	R3UK8X3U3D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MODAFINIL

Official Name

English

NSC-759110

Code

English

CEP-1538

Code

English

THN-102 COMPONENT MODAFINIL

Code

English

CEP 1538

Code

English

ACETAMIDE, 2-((DIPHENYLMETHYL)SULFINYL)-

Systematic Name

English

MODAFINIL [MART.]

Common Name

English

DEP-1538

Code

English

CRL 40476

Code

English

NSC-751178

Code

English

MODAFINIL [USP MONOGRAPH]

Common Name

English

(±)-MODAFINIL

Common Name

English

CRL-40476

Code

English

THN102 COMPONENT MODAFINIL

Code

English

MODAFINIL [USAN]

Common Name

English

2-[(Diphenylmethyl)sulfinyl]acetamide

Systematic Name

English

CRC-40476

Code

English

MODIODAL

Brand Name

English

Modafinil [WHO-DD]

Common Name

English

MODAFINIL [JAN]

Common Name

English

modafinil [INN]

Common Name

English

MODAFINIL CIV

Common Name

English

MODAFINIL [EP MONOGRAPH]

Common Name

English

MODAFINIL [HSDB]

Common Name

English

MODAPHONIL

Brand Name

English

PROVIGIL

Brand Name

English

MODAFINIL [MI]

Common Name

English

MODAFINIL CIV [USP-RS]

Common Name

English

MODAFINIL [VANDF]

Common Name

English

MODAFINIL [ORANGE BOOK]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

NDF-RT

N0000175651

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

FDA ORPHAN DRUG

73793

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

NDF-RT

N0000175729

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

DEA NO.

1680

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

WHO-ATC

N06BA07

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

FDA ORPHAN DRUG

536716

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

NDF-RT

N0000175769

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

WHO-VATC

QN06BA07

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

LIVERTOX

NBK548274

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

Code System Code Type Description

INN

6055

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

DRUG BANK

DB00745

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

NSC

759110

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

MERCK INDEX

M7584

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

Merck Index

LACTMED

Modafinil

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

RS_ITEM_NUM

1445404

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

CAS

112111-49-6

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

SUPERSEDED

NSC

751178

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

MESH

C048833

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

HSDB

7585

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

PUBCHEM

4236

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

SMS_ID

100000080329

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

FDA UNII

R3UK8X3U3D

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

EPA CompTox

DTXSID0023329

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

NCI_THESAURUS

C26661

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

IUPHAR

7555

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

CAS

68693-11-8

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

DRUG CENTRAL

1826

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

USAN

GG-74

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

ChEMBL

CHEMBL1373

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

RXCUI

30125

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

RxNorm

EVMPD

SUB09026MIG

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

WIKIPEDIA

MODAFINIL

Created by admin on Wed Jul 05 23:03:12 UTC 2023 , Edited by admin on Wed Jul 05 23:03:12 UTC 2023

PRIMARY

CHEBI

31859

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

DAILYMED

R3UK8X3U3D

Created by admin on Wed Jul 05 23:03:11 UTC 2023 , Edited by admin on Wed Jul 05 23:03:11 UTC 2023

PRIMARY

Related Record Type Details


					152JRG3T0U

MODAFINIL, (S)-

ENANTIOMER -> RACEMATE


					F202H3PMO2

SODIUM-DEPENDENT DOPAMINE TRANSPORTER

TARGET -> INHIBITOR


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					V63XWA605I

ARMODAFINIL

ENANTIOMER -> RACEMATE

Related Record Type Details


					946LME1J4S

MODAFINIL SULFONE

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA


					54N37HN7N4

MODAFINIL ACID

METABOLITE -> PARENT

Interaction Type:

MAJOR

Qualification:

PLASMA; URINE

Related Record Type Details


					946LME1J4S

MODAFINIL SULFONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					5BAP7W5TXD

MODAFINIL ESTER

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					54N37HN7N4

MODAFINIL ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					R3UK8X3U3D

MODAFINIL

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19689169http://www.drugbank.ca/drugs/DB00745Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19689169http://www.drugbank.ca/drugs/DB00745
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020717A_Provigil_prntlbl.pdf

C_max

T_1/2